Colorectal Cancer, Body Weight and GLP-1 Drugs: Risk and Screening

Excess body weight is an established risk factor for colorectal cancer, and the association is stronger in men than in women ^[2]. An umbrella review of the wider adiposity-and-cancer literature graded the strength of evidence across cancer sites and found colorectal among those with firmer support ^[1]. Two questions follow for anyone on a GLP-1: does the drug itself change cancer risk, and does losing weight change what screening you need. The answers are reassuring and boring respectively, which is the right combination.

The honest summary

• The obesity association is real and sex-dependent. Pooled relative risk for colorectal cancer was 1.37 (95% CI 1.21 to 1.56) for overweight and obese men and 1.07 (95% CI 0.97 to 1.18) for women ^[2].
• Comparing extremes sharpens it. Highest versus lowest BMI quantiles gave 1.59 (95% CI 1.35 to 1.86) for men and 1.22 (95% CI 1.08 to 1.39) for women for colon cancer ^[2].
• An umbrella review graded the wider evidence. Adiposity and cancer associations were assessed for strength and validity across sites rather than reported uncritically ^[1].
• GLP-1 drugs do not appear to raise colorectal cancer risk. A 2026 review found mechanistic work largely suggests antitumor effects, and summarizes the clinical evidence on GLP-1 receptor agonists and colorectal cancer risk ^[3].
• Broader cancer-risk work points the same way. A 2025 analysis in JAMA Oncology examined GLP-1 receptor agonists and cancer risk in adults with obesity ^[5].

What the risk numbers actually are

The meta-analysis of cohort studies is the clearest single source ^[2]. Pooled relative risk of colorectal cancer was 1.37 for overweight and obese men and 1.07 for women, the latter not statistically distinguishable from no effect. Comparing the highest against the lowest BMI quantiles for colon cancer specifically gave 1.59 in men and 1.22 in women.

The sex difference is consistent enough to be worth stating plainly rather than averaging away. The usual explanation involves differences in fat distribution and hormonal environment, but for a reader the practical point is simply that the association is stronger for men.

Do the drugs themselves affect risk?

This was a fair question when these drugs became widespread, and it has been examined. A 2026 review specifically on GLP-1 receptor agonists and colorectal cancer risk notes that the populations taking them — people with type 2 diabetes and obesity — already carry elevated baseline colorectal cancer risk, which is exactly why the question needed asking rather than assuming. Its summary of the mechanistic and preclinical work is that it largely suggests antitumor rather than tumor-promoting effects ^[3].

Wider work on cancer risk with these drugs in adults with obesity points in a similar direction ^[5]. The honest framing is that current evidence is reassuring rather than conclusive, because these are relatively new drugs and cancer outcomes take years to accumulate.

What to actually do

Screening guidance is the practical part. The US Preventive Services Task Force recommendation statement on screening for colorectal cancer sets out who should be screened and from what age ^[4], and that is the document your clinician is working from. Obesity is a risk factor, not a screening criterion, which means it informs your overall risk picture without altering the schedule.

Practical guidance

• Get screened on schedule regardless of weight change. Age and history set the interval, not BMI ^[4].
• Do not treat weight loss as a substitute for screening. It improves a risk factor; it does not detect anything.
• Know your family history. It affects both the starting age and the interval far more than weight does.
• Report rectal bleeding or a persistent change in bowel habit rather than attributing it to a GLP-1.
• Be careful about attributing bowel changes to the drug. Constipation and diarrhea are common on a GLP-1, which makes it easy to explain away a symptom that deserves investigation.